European Medicines Agency (EMA), the drug regulator of the European Union (EU); gave the green light to the application of the third dose of the vaccine developed by Pfizer-BioNTech on adults as part of the fight against the new type of COVID-19 disease.
According to the statements made by the European Medicines Agency, studies on individuals between the ages of 18 and 55 have proven that a third dose strengthens immunity by increasing the level of antibodies in the person. The agency said that healthy adult individuals can receive a third dose of Pfizer-BioNTech vaccine as a supplement, provided that it has been 6 months since the second dose.
Studies on possible side effects of a third dose are ongoing:
EMA also announced that the third dose of booster vaccines developed by Moderna and Pfizer-BioNTech with the help of mRNA technology can be given to people whose immunity is too low 28 days after the second dose. In addition to these, it was noted that there is not enough data on how possible adverse side effects, although very rare, can cause effects after the third dose, and research on this subject continues.
Pfizer-BioNTech and Moderna vaccine, which received a passing grade from the EU as ‘safe and effective’ in December 2020 and January 2021, respectively; Nowadays, it is administered to individuals over 12 years of age in EU countries as two doses.
Countries that are members of the European Union, where the decisions of EMA are advisory; Apps are also free to make their own decisions. The third dose of the vaccine, currently developed by Pfizer-BioNTech, is administered to people with weakened immunity due to different reasons.
44707
